The antigenic structure of the HIV gp120 envelope glycoprotein (scientific article)

cites work (P2860)

Q38753959	"Cytoplasmic domain effects on exposure of co-receptor-binding sites of HIV-1 Env".
Q39300864	A GxxxG-like motif within HIV-1 fusion peptide is critical to its immunosuppressant activity, structure, and interaction with the transmembrane domain of the T-cell receptor
Q35658277	A Mutant Library Approach to Identify Improved Meningococcal Factor H Binding Protein Vaccine Antigens
Q52352443	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.
Q90286963	A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity
Q40606158	A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.
Q77957602	A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein
Q28344177	A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
Q34509949	A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry
Q34741807	A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection
Q38322927	A convenient oxidation of natural glycosphingolipids to their "ceramide acids" for neoglycoconjugation. Bovine serum albumin-glycosylceramide acid conjugates as investigative probes for HIV gp120 coat protein-glycosphingolipid interactions
Q35555194	A critical examination of current HIV therapies
Q39460971	A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1.
Q28743092	A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein
Q37683178	A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation
Q39686823	A fifteen-amino-acid TVB peptide serves as a minimal soluble receptor for subgroup B avian leukosis and sarcoma viruses
Q33803590	A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex
Q36748055	A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120
Q35569049	A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses
Q57032010	A handheld platform for target protein detection and quantification using disposable nanopore strips
Q33796739	A human milk factor susceptible to cathepsin D inhibitors enhances human immunodeficiency virus type 1 infectivity and allows virus entry into a mammary epithelial cell line
Q42717107	A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment
Q27664589	A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity
Q36363866	A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays
Q40523804	A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5.
Q80775196	A novel strategy to mimic discontinuous protective epitopes using a synthetic scaffold
Q47677384	A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals
Q39588870	A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
Q81918606	A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes
Q39682625	A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope
Q34552313	A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.
Q36926701	A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction
Q33522232	A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein
Q34743297	A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers
Q34919985	A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization
Q35140318	A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein
Q45737131	A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1.
Q37192185	A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN.
Q74145681	AIDS in an HIV-seronegative Ghanaian woman with intersubtype A/G recombinant HIV-1 infection
Q33851405	Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4
Q36337888	Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model.
Q36242593	Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry.
Q38703060	Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor
Q39595771	Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication
Q36423960	Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors
Q37349055	Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection.
Q33870292	Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region
Q33961448	Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques
Q45222310	Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.
Q37292398	Advances in antiviral vaccine development
Q34291727	Algal lectins as potential HIV microbicide candidates
Q45735715	Allocation of helper T-cell epitope immunodominance according to three-dimensional structure in the human immunodeficiency virus type I envelope glycoprotein gp120.
Q35058860	Allosteric induction of the CD4-bound conformation of HIV-1 Gp120.
Q28485983	Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity
Q24797088	An algorithm for mapping positively selected members of quasispecies-type viruses
Q34987062	An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes
Q34092668	An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction
Q34485526	An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation.
Q37069430	An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site
Q40104677	An entry-competent intermediate state of the HIV-1 envelope glycoproteins
Q36924968	An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions
Q42086489	An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins
Q52595348	Analysis of HIV-1 envelope evolution suggests antibody-mediated selection of common epitopes among Chinese former plasma donors from a narrow-source outbreak.
Q27472891	Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles
Q37033400	Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
Q33819515	Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization
Q34784833	Analysis of the disulfide bond arrangement of the HIV-1 envelope protein CON-S gp140 ΔCFI shows variability in the V1 and V2 regions
Q40147993	Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis
Q47704819	And the best picture is--the HIV gp120 envelope, please!
Q28243702	Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis
Q33223969	Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor
Q24791794	Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles
Q33377024	Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site
Q36878885	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds
Q27664038	Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged
Q39610187	Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.
Q37701720	Antibody epitopes on g protein-coupled receptors mapped with genetically encoded photoactivatable cross-linkers.
Q29547345	Antibody neutralization and escape by HIV-1
Q36487151	Antibody polyspecificity and neutralization of HIV-1: a hypothesis
Q28256508	Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env
Q26991572	Antibody responses to envelope glycoproteins in HIV-1 infection
Q24536059	Antibody vs. HIV in a clash of evolutionary titans
Q92058300	Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects
Q36446952	Antibody-based inhibitors of HIV infection
Q39682713	Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction
Q33850612	Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition
Q35785338	Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy
Q36267348	Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs
Q36403587	Antigenic conservation and immunogenicity of the HIV coreceptor binding site
Q36973372	Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy.
Q83843766	Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein
Q37547245	Antigenic properties of the HIV envelope on virions in solution
Q27320687	Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells
Q33841969	Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization
Q39081549	Antigenic variations in the CD4 induced sites of the CCR5‐tropic, pathogenic SHIVsf162p3 gp120 variants
Q36447540	Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design
Q35933555	Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins
Q37742876	Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein
Q35847032	Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection
Q35700066	Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120.
Q34050712	Assessment of HIV vaccine development: past, present, and future
Q35956940	Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity
Q33813212	Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo
Q36692987	Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.
Q34022578	Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination
Q40621708	Binding and Neutralization Activity of Human IgG1 and IgG3 from Serum of HIV-Infected Individuals
Q38926812	Binding of HIV-1 virions to α4β 7 expressing cells and impact of antagonizing α4β 7 on HIV-1 infection of primary CD4+ T cells
Q39029460	Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection
Q33780524	Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines
Q36376601	Blockade of HIV-1 infection of New World monkey cells occurs primarily at the stage of virus entry
Q39594695	Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.
Q36977635	Broad HIV-1 neutralization mediated by CD4-binding site antibodies
Q92280921	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
Q34181482	Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family
Q37211421	Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface
Q38065391	Broadly neutralizing antibodies against HIV-1: templates for a vaccine
Q31016954	Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
Q27676767	Burkholderia oklahomensisagglutinin is a canonical two-domain OAA-family lectin: structures, carbohydrate binding and anti-HIV activity
Q34473072	CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection
Q39605953	CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells
Q39549575	CCR5-Mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains
Q36469664	CD4 binding determinant mimicry for HIV vaccine design
Q34462299	CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5
Q28575774	CD4 dependence of gp120IIIB-CXCR4 interaction is cell-type specific
Q39370718	CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity
Q38437455	CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
Q44601067	CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity
Q37730009	CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor
Q33743734	CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies
Q36539317	Caprine arthritis-encephalitis virus envelope surface glycoprotein regions interacting with the transmembrane glycoprotein: structural and functional parallels with human immunodeficiency virus type 1 gp120
Q39127331	Caprine arthritis-encephalitis virus-infected goats can generate human immunodeficiency virus-gp120 cross-reactive antibodies(1).
Q56763445	Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120
Q37858167	Cells under siege: viral glycoprotein interactions at the cell surface
Q34657290	Challenges in the development of an HIV-1 vaccine
Q38753943	Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
Q34471760	Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region
Q34432690	Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.
Q81075242	Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation
Q80952728	Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d
Q34781840	Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.
Q35857631	Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity
Q40720095	Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides
Q34651465	Characterization of the capsid protein glycosylation of adeno-associated virus type 2 by high-resolution mass spectrometry
Q47610272	Characterization of the conformational state and flexibility of HIV-1 glycoprotein gp120 core domain
Q41493875	Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker
Q37596552	Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1
Q45753164	Chemokine receptors and their crucial role in human immunodeficiency virus infection: major breakthroughs in HIV research.
Q45741970	Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env.
Q39186163	Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies
Q39317816	Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
Q35950490	Cloning, expression, purification, crystallization and preliminary crystallographic study of the protein module (BIV2-Helix) in the fusion core of bovine immunodeficiency-like virus (BIV) gp40
Q79125450	Clustering of Th Cell Epitopes on Exposed Regions of HIV Envelope Despite Defects in Antibody Activity
Q37363561	Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins
Q36614954	Combination DNA plus protein HIV vaccines.
Q35914280	Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140
Q33879282	Comparative analysis of the fusion efficiency elicited by the envelope glycoprotein V1-V5 regions derived from human immunodeficiency virus type 1 transmitted perinatally.
Q39484948	Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates
Q36960293	Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes
Q37002517	Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
Q33345100	Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein
Q30360326	Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.
Q34663118	Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques
Q40957217	Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer
Q54049611	Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection.
Q34461554	Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.
Q92136034	Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure
Q36827348	Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors
Q59351001	Conformational Differences Between Functional Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Trimers and Stabilized Soluble Trimers
Q35069459	Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues
Q34934438	Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18
Q35006601	Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions
Q31911259	Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution
Q39607240	Conservation of human immunodeficiency virus type 1 gp120 inner-domain sequences in lentivirus and type A and B retrovirus envelope surface glycoproteins.
Q37153097	Conservation, Compensation, and Evolution of N-Linked Glycans in the HIV-1 Group M Subtypes and Circulating Recombinant Forms
Q36434294	Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites
Q33809112	Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
Q34301728	Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques
Q49155892	Convergent synthesis of oligosaccharides on the gram-scale using cetyl thioglycoside based on a hydrophobically assisted switching phase method.
Q37010374	Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques
Q36499053	Cost-effective production of a vaginal protein microbicide to prevent HIV transmission.
Q37059997	Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes
Q33960361	Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins
Q40281145	Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope
Q37445549	Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
Q33813526	Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope
Q33788810	Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains
Q27661588	Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction
Q35536516	Crystal structure of a fully glycosylated HIV-1 gp120 core reveals a stabilizing role for the glycan at Asn262.
Q35119778	Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose
Q27657377	Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications
Q34502108	Current progress in the development of a prophylactic vaccine for HIV-1.
Q33648180	Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
Q33981547	Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissocia
Q27654848	Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity
Q33840789	Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds
Q77859907	Definition of the alpha 2 region of HLA-DR molecules involved in CD4 binding
Q36571388	Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses
Q34706815	Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env.
Q26991829	Design Challenges for HIV-1 Vaccines Based on Humoral Immunity
Q46958770	Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya
Q40758720	Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry
Q38791942	Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations.
Q34094476	Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies
Q45281480	Detection of IgA-binding sites on human immunodeficiency virus type-1 envelope glycoproteins, Gp120 and Gp41.
Q44325907	Detection of orientation-specific anti-gp120 antibodies by a new N-glycanase protection assay
Q33821658	Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo
Q33796067	Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains
Q39606305	Determination of essential amino acids involved in the CD4-independent tropism of the X4 human immunodeficiency virus type 1 m7NDK isolate: role of potential N glycosylations in the C2 and V3 regions of gp120.
Q37042563	Development of prophylactic vaccines against HIV-1.
Q40455316	Differences in Env and Gag protein expression patterns and epitope availability in feline immunodeficiency virus infected PBMC compared to infected and transfected feline model cell lines.
Q33851094	Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate
Q24541155	Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR
Q34034659	Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection
Q33647608	Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
Q45737326	Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies
Q34545719	Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus
Q33410222	Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection
Q41812551	Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement
Q35857221	Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors
Q39736690	Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU
Q27675486	Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding
Q27618629	Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs
Q26772129	Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion
Q79387613	Dynamic domains and geometrical properties of HIV-1 gp120 during conformational changes induced by CD4 binding
Q34742696	Effect of B-cell depletion on coreceptor switching in R5 simian-human immunodeficiency virus infection of rhesus macaques
Q45675191	Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses
Q34999946	Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates.
Q33571825	Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein
Q44614090	Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity
Q30413840	Efficient on-chip isolation of HIV subtypes
Q30499561	Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions
Q34016706	Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence
Q47570091	Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic
Q22254716	Energetics of the HIV gp120-CD4 binding reaction
Q39154687	Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.
Q40551477	Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa
Q33964006	Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds
Q37192171	Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain
Q38320237	Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor
Q37547162	Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains
Q41572928	Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants
Q40448856	Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies.
Q39590956	Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo
Q33839485	Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys
Q34364045	Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus
Q40548352	Envelope glycoproteins are not required for insertion of host ICAM-1 into human immunodeficiency virus type 1 and ICAM-1-bearing viruses are still infectious despite a suboptimal level of trimeric envelope proteins
Q40621073	Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains
Q41573062	Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies
Q33285288	Epitope mapping: the first step in developing epitope-based vaccines
Q42287446	Epitope specificity of cross-clade neutralizing sera from Chinese HIV-1-positive individuals
Q37426168	Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses
Q42959357	Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.
Q37484850	Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection
Q33883887	Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
Q38061423	Evasion of influenza A viruses from innate and adaptive immune responses.
Q39604142	Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques
Q35627059	Evolution of cell recognition by viruses: a source of biological novelty with medical implications
Q33813025	Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis
Q31034710	Evolution of the uniquely adaptable lentiviral envelope in a natural reservoir host
Q33809419	Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection
Q37596817	Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope
Q64359271	Exploitation of glycosylation in enveloped virus pathobiology
Q36802333	Exploiting the defensive sugars of HIV-1 for drug and vaccine design
Q27481026	Expression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E2 Core Domain That Retains CD81 Binding
Q45006426	Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1.
Q37346068	Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus.
Q35828002	Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization
Q33245070	Extreme sequence divergence but conserved ligand-binding specificity in Streptococcus pyogenes M protein
Q28217208	Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
Q42712576	Fold recognition of the human immunodeficiency virus type 1 V3 loop and flexibility of its crown structure during the course of adaptation to a host
Q37390786	Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc
Q57904660	Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts
Q28743199	Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)
Q33508799	Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region
Q47269144	GalNAc-Specific Soybean Lectin Inhibits HIV Infection of Macrophages through Induction of Antiviral Factors.
Q34353428	Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.
Q27313556	Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy
Q36890344	Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS.
Q36509765	Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
Q33719511	Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies
Q33842152	Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development
Q52591104	Germinal center antibody mutation trajectories are determined by rapid self/foreign discrimination.
Q36032051	Glances in Immunology of HIV and HCV Infection
Q34361498	Glial cells as targets of viral infection in the human central nervous system
Q40406623	Global N-Glycan Site Occupancy of HIV-1 gp120 by Metabolic Engineering and High-Resolution Intact Mass Spectrometry.
Q38884170	Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention
Q21558777	Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development
Q28265115	Glycans, galectins, and HIV-1 infection
Q33826382	Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1
Q38716288	Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers
Q34555891	Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity
Q33967039	Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.
Q39824069	Glycosylation site-specific analysis of clade C HIV-1 envelope proteins
Q40059856	Gp120 V3-dependent impairment of R5 HIV-1 infectivity due to virion-incorporated CCR5.
Q43116285	HIV N-linked glycosylation site analyzer and its further usage in anchored alignment
Q27473020	HIV and the chemokine system: 10 years later
Q28188558	HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors
Q28296162	HIV entry inhibitors: mechanisms of action and resistance pathways
Q37850183	HIV envelope: challenges and opportunities for development of entry inhibitors
Q21559422	HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC
Q40781267	HIV gp120 V(1)/V(2) and C(2)-V(3) domains glycoprotein compatibility is required for viral replication
Q40843036	HIV gp120: double lock strategy foils host defences
Q28660329	HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission
Q35227007	HIV vaccine research: the challenge and the way forward
Q35166836	HIV vaccines 1983-2003.
Q34122331	HIV vaccines for prevention of infection and disease in humans
Q37851950	HIV vaccines: progress to date.
Q38682077	HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.
Q83168652	HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies
Q30248405	HIV-1 and hijacking of the host immune system: the current scenario
Q33552488	HIV-1 and influenza antibodies: seeing antigens in new ways
Q38291704	HIV-1 and its resistance to peptidic carbohydrate-binding agents (CBAs): an overview.
Q35071444	HIV-1 cell entry and advances in viral entry inhibitor therapy
Q73734846	HIV-1 entry - an expanding portal for drug discovery
Q34876042	HIV-1 entry and entry inhibitors as therapeutic agents
Q35753350	HIV-1 entry inhibitors: closing the front door
Q33637946	HIV-1 envelope determinants for cell tropism and chemokine receptor use.
Q38665463	HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies
Q37360774	HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.
Q29619017	HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
Q34328935	HIV-1 gp120 binding to dendritic cell receptors mobilize the virus to the lymph nodes, but the induced IL-4 synthesis by FcepsilonRI+ hematopoietic cells damages the adaptive immunity--a review, hypothesis, and implications
Q35652202	HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells
Q40152011	HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions
Q57788672	HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay
Q27000480	HIV-1 neutralizing antibodies: understanding nature's pathways
Q37484124	HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study
Q37525642	HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations
Q33642318	HIV-1 vaccine development after STEP.
Q36718578	HIV-1 vaccine development: progress and prospects
Q38973555	HIV-2 A-subtype gp125c₂-v₃-c₃ mutations and their association with CCR5 and CXCR4 tropism.
Q47924258	HIV. Envelope's letters boxed into shape
Q38328705	Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site.
Q38014371	Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity
Q33766727	Hierarchical kernel mixture models for the prediction of AIDS disease progression using HIV structural gp120 profiles.
Q34337263	High frequency of virus-specific B lymphocytes in germinal centers of simian-human immunodeficiency virus-infected rhesus monkeys
Q35826509	High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection
Q36237904	High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization
Q37179996	Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India
Q45463275	Highly conserved beta16/beta17 beta-hairpin structure in human immunodeficiency virus type 1 YU2 gp120 is critical for CCR5 binding
Q29307502	Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope
Q28602877	Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
Q39685547	Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding
Q34255654	Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection
Q35101464	Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity
Q37051645	Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma
Q44664935	Human immunodeficiency virus: refolding the envelope
Q37388409	Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors
Q44837410	Human vascular smooth muscle cells possess functional CCR5.
Q36863847	Humoral immunity to HIV-1: neutralization and beyond.
Q35648017	Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques
Q26810040	Hybrid vigor: hybrid methods in viral structure determination
Q24679395	Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design
Q36171536	Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.
Q35132239	Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications
Q39668082	Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins
Q35592911	Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual
Q53851964	Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Q39700192	Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E.
Q36827300	Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes
Q34349528	Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding
Q37038403	Identification of dual-tropic HIV-1 using evolved neural networks
Q90113569	Illuminating the virus life cycle with single-molecule FRET imaging
Q38220506	Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies
Q44646864	Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies
Q36372534	Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region
Q33262275	Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters
Q41925820	Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.
Q37729781	Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
Q36949880	Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response
Q33836042	Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
Q58109386	Improving the Breadth of the Host's Immune Response to Lassa Virus
Q35947769	In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
Q78493198	Inactivation of HIV in blood
Q34340428	Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.
Q49990084	Increased epitope complexity correlated with antibody affinity maturation and a novel binding mode revealed by structures of rabbit antibodies against the third variable loop (V3) of HIV-1 gp120.
Q33810203	Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees
Q33850415	Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants
Q43095098	Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies
Q40883803	Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker
Q33392865	Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing
Q33724169	Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.
Q33842286	Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques
Q33792479	Infection with HIV-1.
Q40096483	Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops
Q47550785	Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane
Q36631937	Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets
Q33849085	Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120
Q28343496	Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
Q37273867	Insight into the mechanisms of aminoglycoside derivatives interaction with HIV-1 entry steps and viral gene transcription
Q38323609	Insights into the trimeric HIV-1 envelope glycoprotein structure
Q34485027	Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus-1 gp41 and equine infectious anemia virus gp45.
Q50116524	Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages.
Q40468582	Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers.
Q33788874	Interaction with CD4 and antibodies to CD4-induced epitopes of the envelope gp120 from a microglial cell-adapted human immunodeficiency virus type 1 isolate
Q38524164	Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides.
Q33797534	Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha
Q77890089	Is an HIV vaccine possible?
Q34885869	Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120.
Q91795737	Isolation of Specific Human Recombinant Antibodies Against Glycoprotein 41 of HIV
Q40047279	Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines
Q28748869	Large-scale sequence analysis of hemagglutinin of influenza A virus identifies conserved regions suitable for targeting an anti-viral response
Q52569620	Ligand accessibility to the HIV-1 Env co-receptor binding site can occur prior to CD4 engagement and is independent of viral tier category.
Q40787903	Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes
Q37910841	Limitations to the structure-based design of HIV-1 vaccine immunogens
Q34046182	Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeys
Q35277600	Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing
Q37010292	Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.
Q52942751	Loopy proteins appear conserved in evolution.
Q38860309	Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission
Q39602333	Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops
Q33810849	Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab
Q40113932	Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia.
Q33819659	Lymphotropic virions affect chemokine receptor-mediated neural signaling and apoptosis: implications for human immunodeficiency virus type 1-associated dementia
Q37073585	Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter
Q36476641	Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5
Q42170932	Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies
Q33810106	Mapping of domains on HIV envelope protein mediating association with calnexin and protein-disulfide isomerase
Q39773434	Mark-specific additive hazards regression with continuous marks
Q36585516	Measuring HIV fusion mediated by envelopes from primary viral isolates
Q37410770	Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment
Q34801630	Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation
Q45411655	Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes
Q42871415	Methods development for Analysis of Partially Deglycosylated Proteins and Application to an HIV Envelope Protein Vaccine Candidate
Q34065197	Microdevices for examining immunological responses of single cells to HIV
Q34042738	Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile
Q36127736	MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency
Q74019913	Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loop
Q37419199	Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.
Q40484043	Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies
Q38290294	Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer
Q27651385	Molecular architecture of native HIV-1 gp120 trimers
Q53695792	Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11.
Q42264259	Molecular biology of liver disorders:the hepatitis C virus and molecular targets for drug development.
Q34071790	Molecular evolution of HIV-1 CRF01_AE Env in Thai patients
Q39748810	Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
Q35888723	Molecular makeup of HIV-1 envelope protein
Q30376865	Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus
Q44649287	Molecular motions of human HIV-1 gp120 envelope glycoproteins
Q28345448	Monoclonal antibodies to conformational epitopes of the surface glycoprotein of caprine arthritis-encephalitis virus: potential application to competitive-inhibition enzyme-linked immunosorbent assay for detecting antibodies in goat sera
Q36404752	Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120.
Q58084786	Motif-Aware PRALINE: Improving the alignment of motif regions
Q34347265	Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein
Q35024164	Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes
Q36980738	Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance
Q40402982	Mutations increasing exposure of a receptor binding site epitope in the soluble and oligomeric forms of the caprine arthritis-encephalitis lentivirus envelope glycoprotein.
Q37010852	N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies
Q30436026	Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood
Q44234474	Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease
Q39934862	Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity
Q34647680	Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy
Q30431941	Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140
Q36246315	Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope
Q35857268	Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection
Q34637968	Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins
Q38945636	Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells
Q35122702	New simian immunodeficiency virus infecting De Brazza's monkeys (Cercopithecus neglectus): evidence for a cercopithecus monkey virus clade
Q43079602	Nonconserved tryptophan 38 of the cell surface receptor for subgroup J avian leukosis virus discriminates sensitive from resistant avian species
Q39699375	Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site
Q39684388	Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein
Q33797989	Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus
Q39856422	On the Physicochemical and Structural Modifications Associated with HIV-1 Subtype B Tropism Transition
Q42041320	PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.
Q34619908	Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.
Q35835515	Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.
Q37081209	Peptide triazole inactivators of HIV-1: how do they work and what is their potential?
Q37034639	Perspectives for a protective HIV-1 vaccine
Q35924919	Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source
Q39406629	Physiological coreceptor use by dual-tropic HIV-1: one plus one equals one.
Q34507076	Plasmodium falciparum rosetting epitopes converge in the SD3-loop of PfEMP1-DBL1α.
Q36577650	Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection
Q37951868	Polyreactive antibodies in adaptive immune responses to viruses
Q33850605	Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques
Q43432407	Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120.
Q36898925	Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo
Q44538700	Preparing for HIV vaccines that induce cytotoxic T lymphocytes
Q38206519	Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).
Q48073666	Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge
Q39551124	Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo
Q73825287	Probing hydrogen bonds in the antibody-bound HIV-1 gp120 V3 loop by solid state NMR REDOR measurements
Q33821896	Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition
Q34419964	Probing the effect of force on HIV-1 receptor CD4.
Q30894431	Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate
Q30358769	Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.
Q36384117	Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors
Q30360451	Production and characterization of monoclonal antibodies sensitive to conformation in the 5HT2c serotonin receptor.
Q37511474	Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins
Q35137125	Progress in the rational design of an AIDS vaccine
Q35864857	Progress on new vaccine strategies against chronic viral infections
Q35165404	Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.
Q35633540	Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge
Q39682485	Properties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIV(SF33A) molecular clones
Q30342038	Prospects for an AIDS vaccine: three big questions, no easy answers.
Q34407994	Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies
Q30760776	Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes
Q64983102	Protein and Glycan Mimicry in HIV Vaccine Design.
Q57202107	Protein glycosylation in infectious disease pathobiology and treatment
Q38574172	Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction
Q34332284	Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus
Q39484956	Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate
Q92376608	Quantifying Anti-HIV Envelope-Specific Antibodies in Plasma from HIV Infected Individuals
Q30479568	Quantum dot-based HIV capture and imaging in a microfluidic channel
Q36747765	R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch
Q27679123	Rabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected Humans
Q29618603	Rapid evolution of the neutralizing antibody response to HIV type 1 infection
Q34342950	Rapid progression to simian AIDS can be accompanied by selection of CD4-independent gp120 variants with impaired ability to bind CD4.
Q45052086	Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes
Q29619511	Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
Q35603504	Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
Q30235024	Recent Insights into the HIV/AIDS Pandemic
Q30353580	Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1
Q34010373	Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.
Q38774504	Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.
Q41732748	Reconstructing the discontinuous and conformational β1/β3-loop binding site on hFSH/hCG by using highly constrained multicyclic peptides
Q34042642	Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections
Q30368774	Reducing the false positive rate in the non-parametric analysis of molecular coevolution.
Q33803939	Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes
Q33984243	Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail
Q35542887	Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.
Q36424574	Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses
Q39616956	Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
Q36098903	Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists
Q34225659	Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine
Q40204965	Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
Q33842989	Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
Q33533351	Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants
Q39605628	Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course
Q34474475	Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys
Q34998032	Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response
Q34295953	Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions
Q39007030	Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity
Q39723388	Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization
Q40638638	Role of the gp120 inner domain beta-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits
Q37308624	Role of unusual O-glycans in intercellular signaling
Q57751823	Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7
Q33797964	Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120
Q74317749	Sequence similarity between the envelope surface unit (SU) glycoproteins of primate and small ruminant lentiviruses
Q33794954	Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.
Q91386304	Serine substitutions are linked to codon usage and differ for variable and conserved protein regions
Q60949698	Shrimp miR-1000 Functions in Antiviral Immunity by Simultaneously Triggering the Degradation of Two Viral mRNAs
Q34023679	Siglecs facilitate HIV-1 infection of macrophages through adhesion with viral sialic acids.
Q47554821	Single-Domain Antibodies As Therapeutics against Human Viral Diseases
Q34142829	Single-molecule analysis of human immunodeficiency virus type 1 gp120-receptor interactions in living cells
Q37002237	Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120.
Q40261449	Specific interaction of CXCR4 with CD4 and CD8alpha: functional analysis of the CD4/CXCR4 interaction in the context of HIV-1 envelope glycoprotein-mediated membrane fusion
Q35857416	Stability of a receptor-binding active human immunodeficiency virus type 1 recombinant gp140 trimer conferred by intermonomer disulfide bonding of the V3 loop: differential effects of protein disulfide isomerase on CD4 and coreceptor binding
Q34361680	Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
Q28534454	Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein
Q37207862	Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein
Q33737656	Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.
Q36559665	Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120
Q91609981	Strategies for inducing effective neutralizing antibody responses against HIV-1
Q33680601	Strategies used by human immunodeficiency virus that allow persistent viral replication
Q37656791	Structural Analysis of the Glycosylated Intact HIV-1 gp120-b12 Antibody Complex Using Hydroxyl Radical Protein Footprinting
Q27663293	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Q27678297	Structural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Miniproteins Revealed by 1.5 Å Cocrystal Structure of gp120 and M48U1
Q27658449	Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120
Q57093739	Structural Insights from HIV-Antibody Coevolution and Related Immunization Studies
Q57292375	Structural Rearrangements Maintain the Glycan Shield of an HIV-1 Envelope Trimer After the Loss of a Glycan
Q56896548	Structural and functional characterization of an epitope in the conserved C-terminal region of HIV-1 gp120
Q30336122	Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies
Q48021409	Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain.
Q27678312	Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16
Q27643185	Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120
Q42615391	Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines
Q38288521	Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120.
Q42707235	Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop
Q24655948	Structural definition of a conserved neutralization epitope on HIV-1 gp120
Q34064787	Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.
Q62572413	Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12
Q27485636	Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein
Q27654249	Structural improvement of unliganded simian immunodeficiency virus gp120 core by normal-mode-based X-ray crystallographic refinement
Q38050485	Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.
Q27327645	Structural plasticity and conformational transitions of HIV envelope glycoprotein gp120
Q39211319	Structural principles controlling HIV envelope glycosylation
Q52338073	Structure and Immune Recognition of the HIV Glycan Shield.
Q41972387	Structure and design of broadly-neutralizing antibodies against HIV.
Q35142291	Structure and immune recognition of trimeric pre-fusion HIV-1 Env.
Q27650903	Structure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data set
Q28654490	Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy
Q27658989	Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility
Q29619014	Structure of a V3-containing HIV-1 gp120 core
Q27759364	Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
Q29616089	Structure of an unliganded simian immunodeficiency virus gp120 core
Q27651112	Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor
Q34045535	Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.
Q24646433	Structure of the measles virus H glycoprotein sheds light on an efficient vaccine
Q34324896	Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry.
Q28071559	Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory
Q36868014	Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus
Q37314536	Structure-based antigen design: a strategy for next generation vaccines
Q44572417	Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
Q37452124	Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc
Q35196671	Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design
Q27629806	Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates
Q45416054	Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine
Q34431854	Sugar-binding proteins from fish: selection of high affinity "lambodies" that recognize biomedically relevant glycans
Q37762275	Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends.
Q30238730	Survivors Remorse: antibody-mediated protection against HIV-1.
Q39992400	Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein
Q41000515	Synthesis of a polymerizable, bivalent glycan mimetic of the HIV envelope spike gp120.
Q64099089	Synthesis of an Undecasaccharide Featuring an Oligomannosidic Heptasaccharide and a Bacterial Kdo-lipid A Backbone for Eliciting Neutralizing Antibodies to Mammalian Oligomannose on the HIV-1 Envelope Spike
Q39422872	T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection
Q28383908	Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activities
Q37179763	Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding
Q30830795	Targeting of HIV gp120 by oligonucleotide-photosensitizer conjugates. Light-induced damages.
Q36539868	Targeting protein-protein interactions by rational design: mimicry of protein surfaces
Q34101087	The Antibody Germline/Maturation Hypothesis, Elicitation of Broadly Neutralizing Antibodies Against HIV-1 and Cord Blood IgM Repertoires
Q26786540	The HIV glycan shield as a target for broadly neutralizing antibodies
Q64120523	The Molecular Basis of pH-Modulated HIV gp120 Binding Revealed
Q39597685	The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors
Q27481009	The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein
Q30376065	The Patterns of Coevolution in Clade B HIV Envelope's N-Glycosylation Sites
Q33883936	The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner
Q36957295	The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors
Q39602963	The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
Q38290769	The anti-HIV pentameric pseudopeptide HB-19 binds the C-terminal end of nucleolin and prevents anchorage of virus particles in the plasma membrane of target cells
Q40444626	The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro
Q29012920	The biology of CCR5 and CXCR4
Q34342352	The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
Q30367176	The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
Q36404101	The changing face of HIV vaccine research
Q34014361	The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention
Q27686831	The crystal structure of HIV CRF07 B'/C gp41 reveals a hyper-mutant site in the middle of HR2 heptad repeat
Q38019332	The design and evaluation of HIV-1 vaccines
Q36155396	The development of CD4 binding site antibodies during HIV-1 infection
Q52581587	The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.
Q34252448	The dysfunction of T follicular helper cells
Q43838812	The efficacy of a new single post-exposure treatment of rabies in mice without vaccination
Q30441682	The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1.
Q57460198	The expanding array of HIV broadly neutralizing antibodies
Q36940646	The frantic play of the concealed HIV envelope cytoplasmic tail.
Q27023390	The hepatitis C virus glycan shield and evasion of the humoral immune response
Q36607016	The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions.
Q27469663	The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts
Q37667754	The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility.
Q33826504	The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses
Q34341843	The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
Q33498727	The phthalocyanine prototype derivative Alcian Blue is the first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential
Q35010683	The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development
Q45662866	The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
Q34632089	The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
Q40164814	The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity
Q34610233	The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes
Q33538298	The role of the viral glycoprotein in HIV-1 persistence.
Q42797346	Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures
Q33789251	Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions
Q37431843	Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity
Q37333789	Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain
Q33854841	Transplanting supersites of HIV-1 vulnerability
Q33933489	Transport, metabolism and elimination mechanisms of anti-HIV agents
Q34332519	Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein
Q93079833	Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells
Q37447351	Two-dimensional gel-based approaches for the assessment of N-Linked and O-GlcNAc glycosylation in human and simian immunodeficiency viruses
Q44530442	Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.
Q43694761	Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry
Q35943810	UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C
Q59355672	Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm
Q34999724	Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies
Q35857683	Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.
Q38976471	Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events
Q30401569	Use of mutual information arrays to predict coevolving sites in the full length HIV gp120 protein for subtypes B and C.
Q39592261	V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies
Q35107518	V3-independent competitive resistance of a dual-X4 HIV-1 to the CXCR4 inhibitor AMD3100
Q61448102	VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120
Q41717140	Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?
Q34178201	Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.
Q39585034	Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits
Q33707333	Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan
Q34203163	Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection
Q37780220	Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges
Q41892359	Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein
Q33843345	Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
Q34343635	Virus receptors in the human central nervous system
Q36602273	Virus-like particles: designing an effective AIDS vaccine
Q38112012	Virus-receptor interactions and receptor-mediated virus entry into host cells
Q33348658	sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates

P6179	Dimensions Publication ID	1007469332
P356	DOI	10.1038/31514
P3181	OpenCitations bibliographic resource ID	3425118
P698	PubMed publication ID	9641684

P50	author	Peter D. Kwong	Q68690794
		Richard T. Wyatt	Q96247131
P2093	author name string	W A Hendrickson
		J Robinson
		J G Sodroski
		R W Sweet
		E Desjardins
P2860	cites work	Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120	Q74277586
		HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor	Q22242268
		Dimeric association and segmental variability in the structure of human CD4	Q24324340
		Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody	Q27759364
		Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons	Q27861091
		The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus	Q28259668
		T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV	Q28646817
		Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1	Q29619512
		Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120	Q33571605
		Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding	Q35845976
		Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys	Q35885915
		Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer	Q36365085
		Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.	Q36623941
		Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies	Q36638240
		CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.	Q39605077
		CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.	Q41151327
		HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope	Q45848174
		Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.	Q48378749
P433	issue	6686
P407	language of work or name	English	Q1860
P921	main subject	HIV	Q15787
P304	page(s)	705-11
P577	publication date	1998-06-18
P1433	published in	Nature	Q180445
P1476	title	The antigenic structure of the HIV gp120 envelope glycoprotein
P478	volume	393

The antigenic structure of the HIV gp120 envelope glycoprotein

scientific article

Reverse relations